Online first
Review paper
Published online: 2024-10-02
Diagnosis and treatment of pleural mesothelioma. State of the art 2024
1
, 1
, 1
Abstract
Pleural mesothelioma is a cancer with a low incidence and poor prognosis. Treatment of pleural mesothelioma includes surgery, radiotherapy and systemic treatment — chemotherapy and immunotherapy. Tri-modal therapy, consisting of surgery, chemotherapy and radiotherapy, remains the standard for radical management. The stage of the tumour at the time of diagnosis usually precludes surgical treatment. Recent years have seen significant advances in the treatment of all cancers. The introduction of dual immunotherapy into everyday practice resulted in a breakthrough in the treatment of pleural mesothelioma. Last year, the combination of nivolumab and ipilimumab is also available in Poland for patients with pleural mesothelioma, irrespective of the histological type. This article reviews reports on pleural mesothelioma therapy based on guidelines from global oncology organisations and results of clinical trials conducted over the past several years.
Keywords: pleural mesotheliomatri-modal therapysystemic treatmentnivolumab with ipilimumab
References
- Wojciechowska U, Didkowska J. Cancer incidence and mortality in Poland in 2020. National Cancer Registry, National Institute of Oncology Maria Skłodowska-Curie – National Research Institute. http://onkologia.org.pl/raporty/.
- Fiertak A, Marek A, Tarabuła-Fiertak M et al. Uważaj na azbest. Kraków 2011. www.ekopsychologia.pl.
- Montanaro F, Rosato R, Gangemi M, et al. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer. 2009; 124(1): 201–207.
- Selby K. Mesothelioma survival rate. 2024. https://www.asbestos.com/mesothelioma/survival-rate/ (26.07.2024).
- Baud M, Strano S, Dechartres A, et al. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg. 2013; 145(5): 1305–1311.
- Pulford E, Huilgol K, Moffat D, et al. Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? Dis Markers. 2017; 2017: 1310478.
- Hiltbrunner S, Fleischmann Z, Sokol ES, et al. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022; 127(11): 1997–2005.
- Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018; 7(5): 543–549.
- Treasure T, Lang-Lazdunski L, Waller D, et al. MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011; 12(8): 763–772.
- Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012; 7(4): 737–743.
- Cao C, Tian D, Park J, et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014; 83(2): 240–245.
- Lim E, Darlison L, Edwards J, et al. MARS 2 Trialists. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020; 10(9): e038892.
- Lim E, Waller D, Lau K, et al. PL03.10 MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. J Thorac Oncol. 2023; 18(11): S36.
- NCCN Guidelines, Mesothelioma Pleural; Version 1 2024. https://www.nccn.org/guidelines/category_1.
- Kindler HL, Ismaila N, Hassan R, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(13): 1343–1373.
- Kim S, Bull DA, Garland L, et al. Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? Ann Thorac Surg. 2019; 107(1): 194–201.
- Rintoul RC, Ritchie AJ, Edwards JG, et al. MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014; 384(9948): 1118–1127.
- Taioli E, van Gerwen M, Mihalopoulos M, et al. Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery. J Thorac Dis. 2017; 9(12): 5423–5433.
- Rimner A, Zauderer MG, Gomez DR, et al. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016; 34(23): 2761–2768.
- Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015; 16(16): 1651–1658.
- Cho BC, Donahoe L, Bradbury PA, et al. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021; 22(2): 190–197.
- Bayman N, Ardron D, Ashcroft L, et al. Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open. 2016; 6(1): e010589.
- Cancer research UK, A trial looking at a type of radiotherapy called PIT in people who have had tests for a type of lung cancer called mesothelioma (PIT). 2018. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-type-radiotherapy-called-pit-people-tests-lung-cancer-called-mesothelioma-pit#undefined.
- Popat S, Baas P, Faivre-Finn C, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(2): 129–142.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14): 2636–2644.
- Zalcman G, Mazieres J, Margery J, et al. French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026): 1405–1414.
- Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019; 7(7): 569–580.
- Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272): 375–386.
- Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022; 33(5): 488–499.
- Fennell DA, Ewings S, Ottensmeier C, et al. CONFIRM trial investigators. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021; 22(11): 1530–1540.
- Okada M, Kijima T, Aoe K, et al. Clinical Efficacy and Safety of Nivolumab: Results of a ulticenter, Opn-label, Single-am, Japanese Phase II study in Malgnant Pleural Mesohelioma (MERIT). Clin Cancer Res. 2019; 25(18): 5485–5492.
- Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J Thorac Oncol. 2018; 13(10): 1569–1576.
- Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5): 623–630.
- Ahmadzada T, Cooper WA, Holmes M, et al. Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. JTO Clin Res Rep. 2020; 1(4): 100075.
- Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019; 5(3): 351–357.
- Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017; 18(9): 1261–1273.
- Zucali PA, Perrino M, Lorenzi E, et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer. 2014; 84(3): 265–270.
- Agatsuma T, Koizumi T, Yasuo M, et al. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed. Jpn J Clin Oncol. 2010; 40(12): 1180–1183.
- Fennell D, Casbard A, Porter C, et al. A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. J Clin Oncol. 2021; 39(15_suppl): 8507–8507.
- Meerbeeck Jv, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer. 1999; 85(12): 2577–2582, doi: 10.1002/(sici)1097-0142(19990615)85:12<2577::aid-cncr13>3.3.co;2-j.
- Jänne P, Wozniak A, Belani C, et al. Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. J Thorac Oncol. 2006; 1(6): 506–512.